110415 ⎘
Reverse transcribing RNA viruses; Details; Retroviridae; Human Immunodeficiency Virus, HIV concerning HIV env Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
COMPOSITIONS COMPRISING HIV-1 ENVELOPES WITH ENGINEERED V1V2 FOR BROAD V3-GLYCAN NEUTRALIZING ANTIBODY BINDING
#2CH505 ENVELOPES TO ENGAGE AND MATURE CD4 BINDING SITE NEUTRALIZING ANTIBODIES
#3HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE
#4HIV Immunogens, Vaccines, and Methods Related Thereto
#5IMMUNIZATION STRATEGIES TO MORE NATURALLY GUIDE THE MATURATION OF ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS (HIV) IN HIV-INFECTED SUBJECTS
#6CH505 ENVELOPES TO ENGAGE AND MATURE CD4 BINDING SITE NEUTRALIZING ANTIBODIES
#7Adenoviral Vectors Comprising Partial Deletions of E3
#8COMPOSITIONS COMPRISING V2 OPT HIV ENVELOPES
#9COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
#10VACCINES HAVING AN ANTIGEN AND INTERLEUKIN-21 AS AN ADJUVANT
#11FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE
#12IMMUNOGENS AND VACCINE COMPOSITIONS AGAINST HIV
#13BASE-COVERED HIV-1 ENVELOPE ECTODOMAINS AND THEIR USE
#14SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN SIX-HELIX BUNDLE PROTEINS
#15EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION
#16HIV VACCINE IMMUNOGENS
#17COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS
#18HIV VACCINES AND METHODS OF USING
#19HIV-1 ENVELOPE STABILIZING MUTATIONS
#20COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HIV INFECTION
#21RECOMBINANT HIV ENV POLYPEPTIDES AND THEIR USES
#22HIV VACCINES AND METHODS OF USING
#23GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR USE
#24IMMUNOGENIC TRIMERS
#25MOLECULAR VACCINES FOR INFECTIOUS DISEASE
#26COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION, GROWTH, SPREAD, OR ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFICACY OF INTERFERON-SENSITIVE VIRUSES
#27SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES
#28HIV-1 VACCINATION AND SAMT-247 MICROBICIDE TO PREVENT HIV-1 INFECTION
#29Extreme Polyvalency Induces Potent Cross-Clade Cellular and Humoral Responses in Rabbits and Non-human Primates
#30METHODS OF ELICITING ANTIBODIES THAT BIND TO FULL-LENGTH GLYCOSYLATED HIV-1 ENV USING MULTIMERIZED ENV CORES
#31Conformationally Specific Viral Immunogens
#32COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
#33COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS
#34MODIFIED ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS AND USE THEREOF
#35AUTOLOGOUS AND ALLOGENIC HIV-1 PROTEINS FOR THE TREATMENT OF LATENT HIV-1 INFECTION
#36COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
#37Trimer Stabilizing HIV Envelope Protein Mutations
#38HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE
#39Epitope focusing by variable effective antigen surface concentration
#40Adenoviral Vectors Comprising Partial Deletions of E3
#41Recombinant HIV-1 envelope proteins and their use
#42CHIMERIC HIV VIRUS-LIKE PARTICLES
#43IMMUNOGENIC TRIMERS
#44COMPOSITIONS COMPRISING V2 OPT HIV ENVELOPES
#45Trimer stabilizing HIV envelope protein mutations
#46FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE
#47FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE
#48HIV vaccines and methods of using
#49Glycan-masked engineered outer domains of HIV-1 gp120 and their use
#50Chimeric molecules and uses thereof
#51Multivalent HIV vaccine boost compositions and methods of use
#52USE OF MODIFIED HIV-1 FOR GENERATING FULLY HUMAN ANTIBODIES
#53HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion envelope conformations
#54HIV vaccination compositions comprising vaccinia VLPS and plant-produced VLPS presenting HIV antigens
#55Poxvirus vectors encoding HIV antigens, and methods of use thereof
#56Antigen Delivery Vectors and Constructs
#57HIV vaccine immunogens
#58COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
#59HIV-1 envelope stabilizing mutations
#60Virtual assistant focused user interfaces
#61Recombinant HIV Env polypeptides and their use
#62FERRITIN NANOPARTICLE DISPLAYING AN HIV TRIMER
#63Conformationally-specific viral immunogens
#64INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS
#65Methods of eliciting antibodies that bind to full-length glycosylated HIV-1 Env using multimerized Env cores
#66Compositions comprising HIV envelopes to induce CH235 lineage antibodies
#67COMPOSITIONS AND METHODS COMPRISING MEASLES VIRUS DEFECTIVE INTERFERING PARTICLES FOR THE PREVENTION OF INFECTIOUS DISEASES
#68Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising Gag, Pol, Vif, and Nef epitopes
#69Vaccines having an antigen and interleukin-21 as an adjuvant
#70Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins
#71Self-assembling insect ferritin nanoparticles
#72Trimer stabilizing HIV envelope protein mutations
#73Compositions and methods for inducing HIV-1 antibodies
#74HIV vaccine formulation
#75Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection
#76Compositions and methods to treat aids
#77Extreme polyvalency induces potent cross-clade cellular and humoral responses in rabbits and non-human primates
#78Multimodal chromatography method for the purification of HIV-1 envelope glycoprotein
#79Epitope focusing by variable effective antigen surface concentration
#80Ebola virus and Marburg virus glycoprotein mucin-like domain replacement expression system used as new vaccine approaches
#81Recombinant viral vectors
#82Scaffolded HIV-1 Env GP140 trimer immunogen
#83Adenoviral vectors comprising partial deletions of E3
#84Antiviral vaccines with improved cellular immunogenicity
#85Trimer stabilizing HIV envelope protein mutations
#86VIRUS LIKE PARTICLE PRODUCTION IN PLANTS
#87HIV envelope glycoprotein immunogens
#88Biochemically stabilized HIV-1 Env trimer vaccine
#89Methods and compositions for treating and preventing HIV
#90Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses
#91MGAT1-Deficient Cells for Production of Vaccines and Biopharmaceutical Products
#92HIV-1 Env fusion peptide immunogens and their use
#93ENGINEERED VARIANTS OF HIV-1 ENV FOR PRESENTATION OF QUARTENARY EPITOPES
#94Broadly Neutralizing Monoclonal Antibodies Against HIV-1 V1V2 Env Region
#95Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
#96Multivalent glycopeptides that tightly bind to target proteins
#97Poxvirus vectors encoding HIV antigens, and methods of use thereof
#98Glycan-masked engineered outer domains of HIV-1 gp120 and their use
#99Compositions and methods for inducing HIV-1 antibodies
#100Directed evolution of multivalent glycopeptides that tightly bind to target proteins
#101Recombinant simian adenoviral vectors encoding a heterologous fiber protein and uses thereof
#102Methods and compositions for treating and preventing HIV
#103Polyclonal antibodies produced using HIV-1 trimeric envelope glycoprotein subunits
#104Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
#105Chimeric molecules and uses thereof
#106Biochemically stabilized HIV-1 Env trimer vaccine
#107SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN SIX-HELIX BUNDLE PROTEINS
#108Compositions comprising HIV envelopes to induce CH235 lineage antibodies
#109Recombinant HIV-1 envelope proteins and their use
#110Multivalent HIV vaccine boost compositions and methods of use
#111Epitope focusing by variable effective antigen surface concentration
#112Adenoviral vectors comprising partial deletions of E3
#113Production of soluble HIV envelope trimers in planta
#114Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
#115Recombinant adenoviruses encoding mosaic human immunodeficiency virus (HIV) Env, Gag, and Pol antigens
#116Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof
#117Virus-like particles with high-density coating for inducing the expression of antibodies
#118Antiviral vaccines with improved cellular immunogenicity
#119Molecular vaccines for infectious disease
#120Recombinant HIV epitopes and uses thereof
#121Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
#122Biochemically stabilized HIV-1 env trimer vaccine
#123Methods and compositions relating to covalently circularized nanodiscs
#124Transgenic VERO-CD4/CCR5 cell line
#125HIV vaccine formulation
#126Optimized HIV envelope gene and expression thereof
#127Engineered outer domain (EOD) of HIV GP120 and mutants thereof
#128Methods and compositions for treating and preventing HIV
#129Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
#130Methods to identify prime and boost immunogens for use in a B cell lineage-based vaccination protocol
#131Compositions and methods to treat AIDS
#132Recombinant viral vectors
#133Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection
#134INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS
#135Vaccines with biomolecular adjuvants
#136Formulation containing TLR agonist and methods of use
#137N-glycan deleted HIV-1 envelope glycoprotein trimers
#138HIV-1 vaccine
#139Scaffolded HIV-1 vaccine immunogens
#140Conformationally Specific Viral Immunogens
#141Polypeptide glycopeptide fragments from the V1/V2 and V3 domains of the HIV-1 envelope protein gp 120
#142DNA antibody constructs and method of using same
#143Immunogenic trimers
#144Recombinant HIV-1 envelope proteins and their use
#145Generation of human anti-HIV-1 ENV monoclonal antibodies with neutralizing activity from humanized mice infected with HIV-1
#146Vaccines having an antigen and interleukin-21 as an adjuvant
#147Stabilized human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using same
#148Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising gag, pol, vif and nef epitopes
#149HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
#150Trimer stabilizing HIV envelope protein mutations
#151Therapeutic peptides and vaccines
#152Methods and compositions related to accelerated humoral affinity
#153Antibody evolution immunogens
#154DNA ANTIBODY CONSTRUCTS AND METHOD OF USING SAME
#155Cross-reactive T-cell epitopes of HIV, SIV, and FIV for vaccines in humans and cats
#156Nucleic acids encoding human immunodeficiency virus type 1 (HIV-1) N-terminal deleted gp120 immunogens and methods of use
#157Consensus/ancestral immunogens
#158Methods and compositions for liposomal formulation of antigens and uses thereof
#159Epitope focusing by variable effective antigen surface concentration
#160Biochemically stabilized HIV-1 Env trimer vaccine
#161Method of inducing an immune response against human immunodeficiency virus comprising administering immunogenic compositions comprising authentic trimeric HIV-1 envelope glycoproteins containing a long linker and tag
#162Engineered outer domain (eOD) of HIV GP120, mutants and use thereof
#163Immunogens for HIV vaccination
#164Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
#165Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof
#166Conformationally specific viral immunogens
#167Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
#168Vaccines with CD40 ligand as an adjuvant
#169Trimer stabilizing HIV envelope protein mutations
#170Immunogenic polypeptides
#171Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag
#172Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
#173Chimpanzee clade E adenovirus nucleic acid-and amino acid-sequences, vectors containing same, and uses thereof
#174Compositions for preventing and/or treating an infection by an HIV-1 virus
#175Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat domain peptides
#176V1/V2 fragments of a HIV-1 envelope glycoprotein
#177DOUBLE ENGINEERED HIV-1 ENVELOPES
#178Stable production of lentiviral vectors
#179HIV vaccine formulation
#180METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF A HIV INFECTION
#181Antibodies With Simultaneous Subsite Specificities To Protein and Lipid Epitopes
#182Recombinant viral vectors
#183Biochemically stabilized HIV-1 Env trimer vaccine
#184Stable immunogen based on inner domain of HIV-1 gp120 for inducing immunity against HIV
#185Compositions comprising CH505 envelopes, and trimers
#186Transgenic Vero-CD4/CCR5 cell line
#187Compositions and methods to treat aids
#188Optimized HIV envelope gene and expression thereof
#189T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines
#190Antiviral vaccines with improved cellular immunogenicity
#191Recombinant HIV-1 envelope proteins and their use
#192Vaccines having an antigen and interleukin-21 as an adjuvant
#193COMPOSITIONS AND METHODS FOR TRANSIENT IMMUNE RESPONSE MODULATION DURING VACCINATION
#194Method and compositions
#195PEPTIDES MIMICKING HIV-1 VIRAL EPITOPES IN THE V2 LOOP FOR THE GP120 SURFACE ENVELOPE GLYCOPROTEIN
#196Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin
#197Adenoviral vectors comprising partial deletions of E3
#198Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof
#199Methods and compositions for liposomal formulation of antigens and uses thereof
#200Attenuated recombinant vesicular stomatitis viruses comprising modified matrix proteins
#201Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins
#202Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
#203Replication-competent VSV-HIV Env vaccines
#204Swarm immunization with envelopes from CH505
#205Viral inhibitory nucleotide sequences and vaccines
#206Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins
#207Influenza antigen delivery vectors and constructs
#208Soluble HIV-1 envelope glycoprotein trimers
#209Materials and methods for producing cleaved, HIV-1 envelope glycoprotein trimers
#210MPER-liposome conjugates and uses thereof
#211Dimeric scaffold peptides comprising HIV-1 GP120 and GP41 epitopes
#212Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region
#213Vaccine and therapeutic delivery system
#214Non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection
#215T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines
#216HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies
#217Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy
#218Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
#219Directed evolution of multivalent glycopeptides that tightly bind to target proteins
#220Multivalent glycopeptides that tightly bind to target proteins
#221Soluble HIV-1 envelope glycoprotein trimers
#222Soluble HIV-1 envelope glycoprotein trimers
#223Approach to produce HIV-1 GP140 envelope protein trimers
#224Approach to produce HIV-1 GP140 envelope protein trimers
#225Method of purifying authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag
#226Authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag
#227Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag
#228HIV-1 antigens with discrete conformational forms in the V1/V2 domain and methods of use thereof
#229Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same
#230Compositions and methods comprising hydrocarbon-stapled polypeptides
#231Mosaic HIV envelope immunogenic polypeptides
#232Methods to improve vector expression and genetic stability
#233HIV-1 vaccine
#234Engineered outer domain (eOD) of HIV gp120 and mutants thereof
#235Adjuvant compositions and methods of use
#236COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
#237Recombinant viral vectors
#238Stabilized HIV-1 peptide constructs comprising the gp120 C5 domain and gp41 hydrophilic domain
#239Methods of inducing an immune response against HIV-1 using recombinant envelopes with improved coverage
#240Cyclic HIV-1 Env V3 glycopeptide immunogens
#241MODIFIED ADENOVIRUS HEXON PROTEIN AND USES THEREOF
#242Replication-competent adenoviral vectors
#243Vaccines with biomolecular adjuvants
#244Human Immunodeficiency Virus type 1 group M consensus and mosaic envelope glycoproteins
#245Vaccine and therapeutic delivery system
#246RECOMBINANT PRODUCTION OF HIV-1 ENVELOPE GLYCOPROTEINS
#247Compositions for preventing and/or treating an infection by an HIV-1 virus
#248Antiviral vaccines with improved cellular immunogenicity
#249Compositions and methods to treat AIDS
#250HIV Antigens and Antibodies
#251Antibody evolution immunogens
#252VACCINE FORMULATION
#253ADJUVANT COMPOSITIONS AND METHODS OF USE
#254HIV therapeutics and methods of making and using same
#255Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
#256Compositions and methods for generating a synthetic antibody
#257SYNTHETIC ENV PROTEINS
#258Virus-like particles, methods of preparation, and immunogenic compositions
#259Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogens
#260Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
#261HIV-1 GP 120 V1/V2 antigens and immunological uses thereof
#262Cytoplasmic Tail Modifications to Boost Surface Expression and Immunogenicity of Envelope Glycoproteins
#263STABILIZED GP120
#264Membrane proximal region of HIV GP41 anchored to the lipid layer of a virus-like particle vaccine
#265METHOD OF INDUCING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS INVOLVING THE ADMINISTRATION OF MPER PEPTIDE-LIPOSOME CONJUGATES
#266Immunogenic compounds comprising HIV GP41 peptide coupled to CRM197 carrier protein
#267Anti-HIV vaccine constructed based on amino acid mutations in attenuated live EIAV vaccine
#268Highly immunogenic peptides derived from the human immunodeficiency virus V2 region
#269Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
#270Antigen delivery vectors and constructs
#271Epitope focusing by variable effective antigen surface concentration
#272Immunogenic compositions comprising FIV and HIV gag antigens
#273Glycopeptide and uses thereof
#274Live, attenuated rubella vector to express vaccine antigens
#275STABLE PEPTIDE MIMETICS OF THE HIV-1 GP41 PRE-HAIRPIN INTERMEDIATE
#276Immunogens for HIV vaccination
#277COMPOSITIONS, METHODS, AND KITS FOR ENHANCING THE IMMUNOGENICITY OF PATHOGENIC ANTIGENS
#278HIV VACCINE
#279Compositions and methods for generating an immune response
#280Chimeric non-integrating lentiviral genomes as vaccines against HIV-1
#281Attenuated recombinant vesicular stomatitis viruses comprising modified mutant matrix proteins
#282IMMUNOGENS BASED ON AN HIV-1 V1V2 SITE-OF-VULNERABILITY
#283GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus
#284HIV consensus envelope sequences and methods for using the same
#285Immunogens comprising human immunodeficiency virus V1/V2 polypeptides
#286Immunogenic complexes of polyanionic carbomers and Env polypeptides and methods of manufacture and use thereof
#287Methods and compositions for liposomal formulation of antigens and uses thereof
#288HIV-1 gp120 mini V3 loop and uses thereof
#289Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
#290Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
#291Method of inducing the production of protective anti-HIV-1 antibodies
#292Influenza antigen delivery vectors and constructs
#293Truncated HIV envelope proteins (ENV), methods and compositions related thereto
#294Glycopeptide and uses thereof
#295Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
#296hTERT sequences and methods for using the same
#297Primary mesenchymal stem cells as a vaccine platform
#298Antigenic polypeptides comprising pre-hairpin intermediate conformations of HIV-1 GP41
#299Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction
#300Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof